Evaluation of the German Guideline for Chronic Pruritus: Results of a Retrospective Study on 385 Patients

Abstract

Objectives: The first guideline for the treatment of chronic pruritus was published in 2005. The recommendations are based mainly on case series studies or expert opinions. This retrospective study aimed at analyzing the outcome of treatment according to the German guidelines in a representative cohort of patients. Methods: 385 consecutive patients with chronic pruritus were evaluated for therapeutic outcome. Results: 268/385 patients (69.6%) reported an antipruritic effect while 117/385 (30.4%) showed no response. Three therapeutic steps were undertaken by 40.3% of the responding patients. Conclusions: Treating pruritus patients according to the German guideline achieved a high response rate. A prolonged treatment period with multiple therapeutic steps was needed by a high number of patients due to the lack of specific antipruritic substances. Given that multiple therapy steps produce a high disease and economic burden, novel target-specific therapies are eligible.

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

“…C hronic pruritus (CP) (of over 6 weeks' duration) has a lifetime prevalence of up to 25.5% (1) and considerably impairs quality of life; thus it represents a worldwide burden (2,3). Although the medical care of patients with CP has improved over recent years, through establishment of specialized itch clinics, a classification system, and well-defined treatment guidelines (4,5), the currently available treatment modalities are not sufficiently efficacious in many patients with CP (6,7). In addition, many of the recommended therapies exhibit adverse effects and cannot be used on a long-term basis.…”

ItchApp©: An App-based eDiary for Assessment of Chronic Pruritus in Clinical Trials

“…C hronic pruritus (CP) is a frequent symptom with a high impact on patients' quality of life (1)(2)(3). To date, there is almost no specific therapy available that successfully alleviates itching (4). New therapies are thus urgently needed.…”

Differences in patient and physician assessment of a dynamic patient reported outcome tool for chronic pruritus

“…The DPS ranges from −100 to +100. For the analyses they were divided into the following categories: 100–81% (very good reduction/very strong impairment); 80–50% (good reduction/strong impairment); 50–31% (moderate reduction/moderate impairment) and 30–0% (no/weak improvement/impairment). Consequently, positive values from 100 to 30 were considered as improvement, negative values from −100 to −30 as impairment and values from −30 to 30 as unchanged or equality.…”